Loading
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
Previous close
$5.75
$0.00 · 0.00%
Regular session · ET · Market data may be delayed.
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
Day range
Current $5.75
52-week range
Current $5.75
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
45
Fair Value
Sentiment
63
Bullish
Risk
66
High Risk
Momentum
72
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
Day range
Current $5.75
52-week range
Current $5.75
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 68.09M USD | — | — | — | 479K USD |
| Gross profit | −68.09M USD | — | — | — | −479K USD |
| Research and development | 17.5M USD | 70.68M USD | 93.79M USD | 61.46M USD | 42.79M USD |
| Selling, general, and administrative | 16.68M USD | 26.09M USD | 33.3M USD | 32.55M USD | 21.23M USD |
| Operating expenses | 34.18M USD | 100.9M USD | 125.47M USD | 104.02M USD | 63.54M USD |
| Interest income | — | 3.96M USD | 7.64M USD | 3.22M USD | 337K USD |
| Interest expense | — | — | — | 24.32M USD | 3K USD |
| Depreciation and amortization | 972K USD | 970K USD | 969K USD | 845K USD | 479K USD |
| Operating income | −102.27M USD | −100.9M USD | −125.47M USD | −104.02M USD | −64.02M USD |
| Net income | −105.61M USD | −96.94M USD | −117.67M USD | −95.64M USD | −54.85M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$17.50
204.35% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 18, 2025 | 1:10 | — | — |
Effective Sep 18, 2025
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.45M0.00%2.3T USD0.03%$381.94+0.63%
Simplify Propel Opportunities ETFSURI858.35K1.13%76.06M USD2.82%$17.06-0.14%
Vanguard Extended Market ETFVXF652.53K0.00%95.4B USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC117.35K0.01%1.32B USD0.60%$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC21.7K0.00%7.56B USD0.43%$57.813+0.20%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR20.9K0.00%45.59B USD0.17%$84.44+0.44%
U.S. Vector Equity Portfolio ETF Class SharesDXUV9.58K0.00%6.18B USD0.26%$68.28+0.25%
Dimensional - US Core Equity 2 ETFDFAC6.03K0.00%88.6B USD0.21%$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTISimplify Propel Opportunities ETFSURIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCU.S. Core Equity 1 Portfolio ETF Class SharesDCORU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
